What are your top takeaways in Gyn Cancers from ESMO 2024?   

Ovarian CA (Immunotherapy) There has been limited success with single agent immunotherapy in ovarian cancer. Three ovarian cancer immunotherapy studies presented at ESMO 2024 are worth noting.ATHENA-COMBO: Rucaparib +/- Nivo as Maintenance in Newly Diagnosed Ovarian Cancer - ATHENA-COMBO Ph3 Tria...